Lincoln Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
170.59
Cr.
PAT
19.98
Cr.
EBITDA
29.04
Cr.
Lincoln Pharmaceuticals Ltd. Q2FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 163.36 | 154.07 | 168.18 | 146.55 | 161.21 |
| Total Income From Operations (Cr.) | 163.36 | 154.07 | 168.18 | 146.55 | 161.21 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 29.04 | 35.60 | 16.61 | 29.41 | 35.13 |
| P/L Before Exceptional Items & Tax (Cr.) | 28.81 | 35.39 | 16.25 | 28.68 | 34.78 |
| P/L After Tax from Ordinary Activities (Cr.) | 19.98 | 27.68 | 11.58 | 20.77 | 26.33 |
| Net Profit/Loss For the Period (Cr.) | 19.98 | 27.68 | 11.58 | 20.77 | 26.33 |
| Basic EPS | 9.98 | 13.82 | 5.78 | 10.37 | 13.15 |
FAQs
Lincoln Pharmaceuticals Ltd. announced its quarterly results for Q2 FY2026 on November 13, 2025.
In Q2 FY2026, Lincoln Pharmaceuticals Ltd. are as follows:
Revenue: ₹170.59 crore
Net Profit: ₹19.98 crore.
For Q2 FY2026, Lincoln Pharmaceuticals Ltd. posted ₹170.59 crore in revenue and ₹19.98 crore in net profit.
Past quarterly results for Lincoln Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.